PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus

NCT04300296 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris

Interventions

DRUG: secukinumab 300 mg Q4W
DRUG: secukinumab 300 mg Q2W
OTHER: Placebo

Sponsor

Novartis Pharmaceuticals